Barclays
LKFT icon

Barclays’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Barclays’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-3,000
Closed -$353K – 7047
2019
Q1 		$353K Buy
+3,000
New +$302K ﹤0.01% 4398
2018
Q4 		– Sell
-3,000
Closed -$337K – 7074
2018
Q3 		$337K Buy
+3,000
New +$317K ﹤0.01% 4587

Other funds holding LKFT

Gilead Sciences
Gilead Sciences Foster City, California $1.46B AUM 71.23% 1-Year Est. Return
Prosight Management
Prosight Management Dallas, Texas $515M AUM 2.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $234B AUM 43.58% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $123B AUM 30.05% 1-Year Est. Return
HRT Financial
HRT Financial New York $57.2B AUM 52.85% 1-Year Est. Return

Barclays's LKFT Position: Q3 2026 in Review

Barclays increased its Lakefront Biotherapeutics American Depositary Shares (LKFT) stake by 1,037% in Q3 2026, buying an estimated $35.4K and bringing the position to 1,353 shares worth $40.1K. The position accounts for ﹤0.01% of the portfolio, ranked #4623.

Barclays first reported a position in LKFT in Q2 2015 and has held it in 27 quarters since. The position peaked at $12.1M in Q4 2019. 67 funds tracked by Wall St. Rank hold LKFT as of Q3 2026.

  • Barclays held 1,353 shares of Lakefront Biotherapeutics American Depositary Shares worth $40.1K as of Q3 2026.
  • Barclays bought 1,234 Lakefront Biotherapeutics American Depositary Shares shares in Q3 2026, an estimated $35.4K.
  • Lakefront Biotherapeutics American Depositary Shares made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #4623 holding.
  • Barclays first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q2 2015 and has held it in 27 quarters since.
  • Barclays's Lakefront Biotherapeutics American Depositary Shares position peaked at $12.1M in Q4 2019.
  • 67 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.